View Older Stories View More Recent Stories

Aug 11, 2021 07:00AM Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
Jul 30, 2021 08:00AM Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
Jul 28, 2021 08:00AM Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
Jun 24, 2021 08:00AM Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
Jun 2, 2021 06:00AM Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care
Jun 1, 2021 09:00AM Optinose to Present at the Jefferies Virtual Healthcare Conference
May 5, 2021 07:00AM Optinose Reports First Quarter 2021 Financial Results and Operational Updates
Apr 28, 2021 08:30AM Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
Apr 27, 2021 06:00AM New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day
Apr 12, 2021 04:15PM Optinose to Present at the Needham Virtual Healthcare Conference
Mar 3, 2021 07:00AM Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
Feb 17, 2021 05:23PM Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
Jan 25, 2021 04:30PM Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 21, 2020 10:00AM Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 1, 2020 04:30PM Optinose Announces Changes to Board of Directors
Nov 5, 2020 07:00AM Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
Oct 22, 2020 07:11AM OptiNose (OPTN) Announces Preliminary Q3 XHANCE Net Revenue of $15.4 Million
Oct 22, 2020 07:00AM Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million
Sep 29, 2020 09:30AM OptiNose (OPTN) Announces New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays
Sep 29, 2020 09:30AM New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays
Sep 14, 2020 08:00AM Optinose to Present at the Cantor Virtual Global Healthcare Conference
Aug 4, 2020 07:00AM Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights 
Jul 30, 2020 04:01PM Optinose Announces Reporting Date for Second Quarter 2020 Financial Results
Jul 29, 2020 04:01PM Optinose names Catherine E. Owen as Director
Jul 8, 2020 04:18PM OptiNose (OPTN) Announces XHANCE Co-Promotion Agreement with Kaleo
Jul 8, 2020 04:15PM Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
Jun 30, 2020 08:06AM OptiNose (OPTN) Begins Development of New Product Candidate, OPN-019
Jun 30, 2020 08:00AM Optinose Announces Anti-COVID-19 Product Candidate
Jun 22, 2020 08:30AM Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 19, 2020 10:00AM Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal
May 27, 2020 04:30PM Optinose to Host its Annual Meeting of Stockholders in Virtual Format
May 26, 2020 09:00AM Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference
May 14, 2020 04:15PM Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
May 7, 2020 04:01PM Optinose Reports First Quarter 2020 Financial Results and Operational Updates
Apr 30, 2020 04:15PM Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020
Mar 5, 2020 06:30AM Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights
Feb 27, 2020 04:30PM Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020
Feb 19, 2020 07:00AM Optinose Appoints Victor Clavelli as Chief Commercial Officer
Dec 17, 2019 08:30AM Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial
Nov 26, 2019 04:01PM Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference
Nov 12, 2019 04:01PM Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
Nov 1, 2019 08:00AM Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019
Oct 4, 2019 08:00AM Optinose Appoints Michael Richardson to New Position of Vice President, Business Development
Sep 27, 2019 08:00AM Optinose to Present at the 2019 Cantor Global Healthcare Conference
Sep 26, 2019 07:07AM OptiNose (OPTN) Announces License Agreement Related to ONZETRA XSAIL
Sep 26, 2019 07:00AM OptiNose Announces License Agreement Related to ONZETRA XSAIL
Sep 17, 2019 04:01PM Optinose Announces Departure of Chief Commercial Officer
Sep 17, 2019 04:01PM Optinose Announces Departure of Chief Commercial Officer
Sep 12, 2019 04:05PM Optinose Announces $150 Million Debt Financing from Pharmakon
Sep 12, 2019 04:05PM Optinose Announces $150 Million Debt Financing from Pharmakon
View More Recent Stories View Older Stories